PDCD1 and neuropathy: When factoring in patients’ smoking history, there was a significantly lower prevalence of documented neuropathy associated with PD-1 inhibitor exposure in the current-smoker group when compared to the never-smoker group (Table 1; OR 0.716, 95% CI 0.523–0.980, p = 0.0368).